Correction to Staging FDG-avidity in extranodal marginal zone lymphoma (EMZL) by disease location

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2024-06-21 DOI:10.1002/hon.3223

引用次数: 0

Abstract

Alderuccio, J.P., Saul, E.E., Stanchina, Polar, M.K, M., Sassi, R.H., Zhao, W., Moskowitz, C.H., Reis, I., Kuker, R.A., Lossos, I.S. (2023), Staging FDG-avidity in extranodal marginal zone lymphoma (EMZL) by disease location. Hematological Oncology, 41: 103–104. https://doi.org/10.1002/hon.3163_64

In the author byline, the middle initials of the authors are missing, and the sequence is incorrect.

The incorrect author byline is:

J. P. Alderuccio, E. Edelman Saul, M. Stanchina, R. Hennemann Sassi, W. Zhao, C. Moskowitz, I. Reis, R. Kuker, I. Lossos, M. Polar

The correct author byline should be:

J.P. Alderuccio, E. Edelman Saul, M.D. Stanchina, M.K. Polar, R. Henneman Sassi, W. Zhao, C.H. Moskowitz, I. Reis, R.A. Kuker, I.S. Lossos

查看原文本刊更多论文

按疾病部位对结节外边缘区淋巴瘤（EMZL）的 FDG 空洞进行分期更正

Alderuccio，J.P.，Saul，E.E.，Stanchina，Polar，M.K，M.，Sassi，R.H.，Zhao，W.，Moskowitz，C.H.，Reis，I.，Kuker，R.A.，Lossos，I.S.（2023年），按疾病位置对结外边缘区淋巴瘤（EMZL）的FDG-无效进行分期。血液肿瘤学》，41：103-104。https://doi.org/10.1002/hon.3163_64In 作者署名，作者中间首字母缺失，顺序也不正确。错误的作者署名是：J.P. Alderuccio, E. Edelman Saul, M. Stanchina, R. Hennemann Sassi, W. Zhao, C. Moskowitz, I. Reis, R. Kuker, I. Lossos, M. Polar正确的作者署名应该是：J.P. Alderuccio, E. Edelman Saul, M.D. Stanchina, M.K. Polar, R. Henneman Sassi, W. Zhao, C.H. Moskowitz, I. Reis, R.A. Kuker, I.S. Lossos

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.